I-Corps: SOLUTION MICROARRAY MULTIPLEXED BIOMARKER IMMUNOASSAYS

没有一种生物标志物能够提供可靠诊断或治疗患者所需的所有信息。因此，临床诊断的主要目标是有效地分析一组诊断生物标志物。尽管有这种众所周知的需求，但几乎不存在具有成本效益的、灵敏的和定量的多蛋白（多重）诊断免疫测定。虽然数百篇研究文章已经描述了多重免疫测定，但由于当多种检测抗体混合在一起进入一种溶液时发生的背景增加和/或串扰，它们不能被验证用于临床应用。该团队利用专有的微流控技术，通过创建多路免疫测定微阵列来为这个问题提供创新的解决方案，其中不会发生检测抗体的混合。该项目将推进微流体科学和技术，并为利用蛋白质组学的基础科学研究提供新的工具。除了科学和技术进步，该项目还将推进将实验室研究成果转化为商业产品和服务的概念和方法。该项目将增加对多重生物标志物测定和蛋白质组学领域客户需求的了解。该项目还将提出最有效和商业上可行的方法，将该技术带给用户。该团队设想该项目通过开发强大的，用户友好的多重免疫测定来造福社会，通过提供强大的和用户友好的蛋白质测定来加强临床诊断和基础生物学研究。由于该项目的目标是技术商品化，因此该项目的成功将通过经济和技术手段直接为社会提供巨大的效益。所有三个参与人员（创业带头人，PI和导师）也将学习新的想法和方法，以及实际动手经验，这是这个项目的一部分。这些经验肯定不仅会影响这一特定技术的商业化努力，而且会影响未来的其他商业化项目。此外，技术转让经验教训也将通过PI教授的课程以及一次性讲座纳入课堂。

No one biomarker gives all the information needed to diagnose or treat a patient reliably. Thus a major goal of clinical diagnostics is to efficiently analyze a panel of diagnostic biomarkers. Despite this well-known need, cost-effective, sensitive, and quantitative multi-protein (multiplexed) diagnostic immunoassays hardly exist. While hundreds of research articles have described multiplexed immunoassays, they cannot be validated for clinical applications due to increased background and or cross-talk that occur when multiple detection antibodies are mixed together into one solution. The team utilizes a proprietary microfluidic technology to provide an innovative solution to this problem by creating multiplexed immunoassay microarrays where no mixing of detection antibodies occurs. The project will advance microfluidic science and technology as well as provide new tools for use in basic science studies that utilize proteomics. In addition to science and technology advancement, this project will advance concepts and methods in translating laboratory research results into commercial products and services. The project will increase understanding of customer needs in the area of multiplexed biomarker assays and proteomics. The project will also propose the most efficient and commercially-viable methods to bring the technology to users.The team envisions the project to benefit society through development of robust, user-friendly, multiplexed immunoassays that will enhance clinical diagnostics as well as basic biology studies through providing robust and user-friendly protein assays. As the project goal is technology commercialization, success of this project will directly provide a large benefit to society through economic as well as technological means. All three personnel involved (entrepreneurial lead, PI, and mentor) will also learn new ideas and methodology as well as actual hands on experience that is part of this project. These experiences will surely impact not only this particular technology commercialization effort but other commercialization projects in the future. Additionally, the technology transfer lessons learned will also be incorporated into the classroom through courses taught by the PI as well as through one-time lectures.